TASP0434299: A novel pyridopyrimidin-4-one derivative as a radioligand for vasopressin V1B receptor

Kazumi Koga, Mitsukane Yoshinaga, Yoshikatsu Uematsu, Yuji Nagai, Naoki Miyakoshi, Yoko Shimoda, Masayuki Fujinaga, Takafumi Minamimoto, Ming Rong Zhang, Makoto Higuchi, Norikazu Ohtake, Tetsuya Suhara, Shigeyuki Chaki

研究成果: ジャーナルへの寄稿学術論文査読

3 被引用数 (Scopus)

抄録

A novel pyridopyrimidin-4-one derivative, N-tert-butyl-2-[2-(3-methoxyphenyl)-6-[3-(morpholin-4-yl)propoxy]-4-oxopyrido[2,3-d]pyrimidin-3(4H)-yl]acetamide (TASP0434299), was characterized as a radioligand candidate for arginine vasopressin 1B (V1B) receptor. TASP0434299 exhibited high binding affinities for human and rat V1B receptors with IC50 values of 0.526 and 0.641 nM, respectively, and potent antagonistic activity at the human V1B receptor with an IC50 value of 0.639 nM without apparent binding affinities for other molecules at 1 μM. [3H]TASP0434299 bound to membranes expressing the human V1B receptor as well as those prepared from the rat anterior pituitary in a saturable manner. The binding of [3H]TASP0434299 to the membranes was dose-dependently displaced by several ligands for the V1B receptor. In addition, the intravenous administration of [3H]TASP0434299 to rats produced a saturable radioactive accumulation in the anterior pituitary where the V1B receptor is enriched, and it was dose-dependently blocked by the oral administration of 2-[2-(3-chloro-4-fluorophenyl)-6-[3-(morpholin-4-yl)propoxy]-4-oxopyrido[2,3-d] pyrimidin-3(4H)-yl]-N-isopropylacetamide hydrochloride, a V1B receptor antagonist, indicating that [3H]TASP0434299 can be used as an in vivo radiotracer to measure the occupancy of the V1B receptor. Finally, the intravenous administration of [11C]TASP0434299 provided positron emission tomographic images of the V1B receptor in the pituitary in an anesthetized monkey, and the signal was blocked by pretreatment with an excess of unlabeled TASP0434299. These results indicate that radiolabeled TASP0434299 is the first radioligand to be capable of quantifying the V1B receptor selectively in both in vitro and in vivo studies and will provide a clinical biomarker for determining the occupancy of the V1B receptor during drug development or for monitoring the levels of the V1B receptor in diseased conditions.

本文言語英語
ページ(範囲)495-508
ページ数14
ジャーナルJournal of Pharmacology and Experimental Therapeutics
357
3
DOI
出版ステータス出版済み - 01-06-2016
外部発表はい

All Science Journal Classification (ASJC) codes

  • 分子医療
  • 薬理学

フィンガープリント

「TASP0434299: A novel pyridopyrimidin-4-one derivative as a radioligand for vasopressin V1B receptor」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル